Study of MAP0010 in Asthmatic Children and Adolescents

Completed · Phase 2 · Has a placebo group

Conditions studied: Asthma

In brief

The objectives of this study are to evaluate the efficacy, tolerability and pharmacokinetics of 2 doses of MAP0010 (Unit Dose Budesonide) in asthmatic children/adolescents.

Key facts

Study ID
NCT00697801
Run by
Allergan
People needed
208
Starts
2006-07-01
Expected to finish
2006-12-01
Last updated by the study team
2014-01-09

Who can join

Age: 1 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.